AIRLINK 74.11 Increased By ▲ 1.11 (1.52%)
BOP 5.30 Decreased By ▼ -0.05 (-0.93%)
CNERGY 4.33 Increased By ▲ 0.02 (0.46%)
DFML 27.70 Decreased By ▼ -0.85 (-2.98%)
DGKC 78.30 Increased By ▲ 4.01 (5.4%)
FCCL 20.63 Increased By ▲ 0.28 (1.38%)
FFBL 31.82 Increased By ▲ 0.92 (2.98%)
FFL 10.22 Increased By ▲ 0.16 (1.59%)
GGL 10.47 Increased By ▲ 0.08 (0.77%)
HBL 117.20 Increased By ▲ 1.23 (1.06%)
HUBC 134.77 Increased By ▲ 2.57 (1.94%)
HUMNL 6.74 Increased By ▲ 0.06 (0.9%)
KEL 4.19 Increased By ▲ 0.16 (3.97%)
KOSM 4.77 Increased By ▲ 0.17 (3.7%)
MLCF 39.13 Increased By ▲ 0.59 (1.53%)
OGDC 135.20 Increased By ▲ 1.35 (1.01%)
PAEL 23.50 Decreased By ▼ -0.33 (-1.38%)
PIAA 26.62 Decreased By ▼ -0.51 (-1.88%)
PIBTL 7.00 Increased By ▲ 0.24 (3.55%)
PPL 113.53 Increased By ▲ 0.73 (0.65%)
PRL 27.80 Decreased By ▼ -0.36 (-1.28%)
PTC 14.55 Decreased By ▼ -0.34 (-2.28%)
SEARL 56.00 Decreased By ▼ -0.42 (-0.74%)
SNGP 65.80 No Change ▼ 0.00 (0%)
SSGC 11.00 Decreased By ▼ -0.01 (-0.09%)
TELE 9.05 Increased By ▲ 0.03 (0.33%)
TPLP 11.89 Decreased By ▼ -0.01 (-0.08%)
TRG 69.70 Increased By ▲ 0.60 (0.87%)
UNITY 23.67 Decreased By ▼ -0.04 (-0.17%)
WTL 1.34 Increased By ▲ 0.01 (0.75%)
BR100 7,512 Increased By 77.3 (1.04%)
BR30 24,501 Increased By 281.3 (1.16%)
KSE100 72,210 Increased By 850.4 (1.19%)
KSE30 23,860 Increased By 293.5 (1.25%)
World

Germany's COVID-19 vaccination centres to hit capacity by end of March

  • Germany has so far been starved of shots as drugmakers faced production problems, but shortages are likely to ease as deliveries accelerate.
  • BioNTech's shot, made in partnership with US drug company Pfizer, was the first to win approval for use in the European Union.
Published February 10, 2021

BERLIN: Germany will run up against limits on its capacity to inoculate people against COVID-19 by the end of March, health ministry documents showed, as an expected increase in supply puts its network of vaccination centres to the test.

Germany has so far been starved of shots as drugmakers faced production problems, but shortages are likely to ease as deliveries accelerate, according to a revised vaccine strategy released by the health ministry on Wednesday.

The strategy update came as German biotech startup BioNTech launched a new facility in the German town of Marburg, expecting first vaccines made there to be distributed in early April.

BioNTech's shot, made in partnership with US drug company Pfizer, was the first to win approval for use in the European Union.

Germany is also getting vaccines from Moderna and AstraZeneca. The Pfizer and Moderna shots need to be kept frozen, while Astra's can be stored in a fridge, making it suitable for administration by family doctors.

Around 2.4 million people have been vaccinated in Germany, or 2.9% of the population, since it started vaccinations in December, health ministry data showed.

Initial shortages should give way in the second quarter to more abundant supply, when Germany expects to receive 77 million vaccine doses. Chancellor Angela Merkel has promised shots to all adults who want one by the end of the summer.

To reach this target, vaccinations will be offered at general practitioners' clinics, working in parallel with the existing network of more than 400 vaccination centres, the plan document read.

"It is becoming clear that the vaccination centres will have to continue to operate for a longer period of time, even after doctors' practices are involved," it read.

In the plan, Germany's Institute for Statutory Health Care (Zi) recommended increasing the daily capacity of vaccination centres to 300,000 from 200,000 to meet targets.

According to Zi calculations and based on drugmakers' delivery commitments, Germany will be able to inoculate around three million people a week from May and administer around one million shots a day by the end of June.

Comments

Comments are closed.